Effects of growth conditions on the barrier properties of a human skin equivalent

Priya Batheja, Yifan Song, Philip Wertz, Bozena Michniak-Kohn

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: Development of transdermal and topical formulations requires extensive skin permeation testing and the availability of reproducible test models. We have worked on development of a Human Skin Equivalent (HSE) by culture with a combination of additives, including the PPAR-α agonist clofibrate, in order to simulate the cutaneous barrier of human skin. Methods: HSEs were constructed by culturing human keratinocytes on dermal matrices consisting of human fibroblasts and collagen and cultured in specific growth conditions (combination of clofibrate, ascorbic acid and fatty acids). The resulting HSEs were characterized for their morphology, lipid composition and permeability profile and compared to human skin and EpidermFT®. Results: The unique media growth additives combination normalized the lipid profile and significantly increased the permeability barrier of the HSEs to caffeine and hydrocortisone (p∈<∈0.05). The HSEs overestimated the permeation of most compounds by 2-7 fold as compared to human skin. The permeability profiles obtained though were very similar and not significantly different (p∈<∈0.05) from those of EpidermFT®. Conclusions: Culture with the growth media additives combination produced a pronounced effect on the permeability barrier of the HSEs. Further validation of permeability with additional agents could comprise the first step toward their use in skin permeability screening.

Original languageEnglish (US)
Pages (from-to)1689-1700
Number of pages12
JournalPharmaceutical research
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Skin
Permeability
Growth
Clofibrate
Permeation
Lipids
Peroxisome Proliferator-Activated Receptors
Fibroblasts
Caffeine
Ascorbic Acid
Hydrocortisone
Screening
Human Development
Collagen
Fatty Acids
Keratinocytes
Availability
Testing
Chemical analysis

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Keywords

  • Clofibrate
  • Permeability
  • Reconstructed skin
  • Skin equivalents
  • Transdermal

Cite this

Batheja, Priya ; Song, Yifan ; Wertz, Philip ; Michniak-Kohn, Bozena. / Effects of growth conditions on the barrier properties of a human skin equivalent. In: Pharmaceutical research. 2009 ; Vol. 26, No. 7. pp. 1689-1700.
@article{de373a23045546938aaf9b8056761ec7,
title = "Effects of growth conditions on the barrier properties of a human skin equivalent",
abstract = "Purpose: Development of transdermal and topical formulations requires extensive skin permeation testing and the availability of reproducible test models. We have worked on development of a Human Skin Equivalent (HSE) by culture with a combination of additives, including the PPAR-α agonist clofibrate, in order to simulate the cutaneous barrier of human skin. Methods: HSEs were constructed by culturing human keratinocytes on dermal matrices consisting of human fibroblasts and collagen and cultured in specific growth conditions (combination of clofibrate, ascorbic acid and fatty acids). The resulting HSEs were characterized for their morphology, lipid composition and permeability profile and compared to human skin and EpidermFT{\circledR}. Results: The unique media growth additives combination normalized the lipid profile and significantly increased the permeability barrier of the HSEs to caffeine and hydrocortisone (p∈<∈0.05). The HSEs overestimated the permeation of most compounds by 2-7 fold as compared to human skin. The permeability profiles obtained though were very similar and not significantly different (p∈<∈0.05) from those of EpidermFT{\circledR}. Conclusions: Culture with the growth media additives combination produced a pronounced effect on the permeability barrier of the HSEs. Further validation of permeability with additional agents could comprise the first step toward their use in skin permeability screening.",
keywords = "Clofibrate, Permeability, Reconstructed skin, Skin equivalents, Transdermal",
author = "Priya Batheja and Yifan Song and Philip Wertz and Bozena Michniak-Kohn",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s11095-009-9879-1",
language = "English (US)",
volume = "26",
pages = "1689--1700",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "7",

}

Effects of growth conditions on the barrier properties of a human skin equivalent. / Batheja, Priya; Song, Yifan; Wertz, Philip; Michniak-Kohn, Bozena.

In: Pharmaceutical research, Vol. 26, No. 7, 01.07.2009, p. 1689-1700.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of growth conditions on the barrier properties of a human skin equivalent

AU - Batheja, Priya

AU - Song, Yifan

AU - Wertz, Philip

AU - Michniak-Kohn, Bozena

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Purpose: Development of transdermal and topical formulations requires extensive skin permeation testing and the availability of reproducible test models. We have worked on development of a Human Skin Equivalent (HSE) by culture with a combination of additives, including the PPAR-α agonist clofibrate, in order to simulate the cutaneous barrier of human skin. Methods: HSEs were constructed by culturing human keratinocytes on dermal matrices consisting of human fibroblasts and collagen and cultured in specific growth conditions (combination of clofibrate, ascorbic acid and fatty acids). The resulting HSEs were characterized for their morphology, lipid composition and permeability profile and compared to human skin and EpidermFT®. Results: The unique media growth additives combination normalized the lipid profile and significantly increased the permeability barrier of the HSEs to caffeine and hydrocortisone (p∈<∈0.05). The HSEs overestimated the permeation of most compounds by 2-7 fold as compared to human skin. The permeability profiles obtained though were very similar and not significantly different (p∈<∈0.05) from those of EpidermFT®. Conclusions: Culture with the growth media additives combination produced a pronounced effect on the permeability barrier of the HSEs. Further validation of permeability with additional agents could comprise the first step toward their use in skin permeability screening.

AB - Purpose: Development of transdermal and topical formulations requires extensive skin permeation testing and the availability of reproducible test models. We have worked on development of a Human Skin Equivalent (HSE) by culture with a combination of additives, including the PPAR-α agonist clofibrate, in order to simulate the cutaneous barrier of human skin. Methods: HSEs were constructed by culturing human keratinocytes on dermal matrices consisting of human fibroblasts and collagen and cultured in specific growth conditions (combination of clofibrate, ascorbic acid and fatty acids). The resulting HSEs were characterized for their morphology, lipid composition and permeability profile and compared to human skin and EpidermFT®. Results: The unique media growth additives combination normalized the lipid profile and significantly increased the permeability barrier of the HSEs to caffeine and hydrocortisone (p∈<∈0.05). The HSEs overestimated the permeation of most compounds by 2-7 fold as compared to human skin. The permeability profiles obtained though were very similar and not significantly different (p∈<∈0.05) from those of EpidermFT®. Conclusions: Culture with the growth media additives combination produced a pronounced effect on the permeability barrier of the HSEs. Further validation of permeability with additional agents could comprise the first step toward their use in skin permeability screening.

KW - Clofibrate

KW - Permeability

KW - Reconstructed skin

KW - Skin equivalents

KW - Transdermal

UR - http://www.scopus.com/inward/record.url?scp=67349115999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349115999&partnerID=8YFLogxK

U2 - 10.1007/s11095-009-9879-1

DO - 10.1007/s11095-009-9879-1

M3 - Article

VL - 26

SP - 1689

EP - 1700

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 7

ER -